Get notified when AKTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Material Weaknesses (new) — The company discloses material weaknesses in internal control over financial reporting, a significant governance red flag.
- Going Concern (new) — The auditor's report includes a going-concern explanatory paragraph, signaling substantial doubt about the company's ability to continue operating.
- Dilution / Overhang (new) — The registration covers up to 2.5 million ADSs, which would represent 58.8% of the 1,750,356 ADSs outstanding as of June 26, 2026, creating massive potential dilution and resale overhang.
Akari Therapeutics registers up to 2.5M ADSs for resale by White Lion under a $25M equity line
Filed June 26, 2026 · ~2 min read
Key Changes
-
high
The offering is a resale registration of up to 2.5 million ADSs (representing 200 billion ordinary shares) by selling stockholder White Lion; the company receives no proceeds from those resales.
The Offering verify on EDGAR → -
high
Akari may receive up to $25.0 million in gross proceeds from sales of ordinary shares to White Lion under the Purchase Agreement, at its discretion, for working capital and general corporate purposes.
Use of Proceeds verify on EDGAR → -
high
The company has identified material weaknesses in its internal control over financial reporting.
Risk Factors verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade AKTX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 30, 2026 · How we verify